Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Baxalta Gmbh patents


Recent patent applications related to Baxalta Gmbh. Baxalta Gmbh is listed as an Agent/Assignee. Note: Baxalta Gmbh may have other listings under different names/spellings. We're not affiliated with Baxalta Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Baxalta Gmbh-related inventors


Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph

The present invention provides, among other aspects, storage stable aqueous formulations of immunoglobulins with histidine at a mildly acidic to neutral ph. The present invention also provides methods for stabilizing immunoglobulin compositions by formulating with histidine at a mildly acidic to neutral ph. ... Baxalta Gmbh

Detection of cho-mif contaminations

The invention concerns a detection method to enable the detection of complexes formed between antibodies and antigen which is endogenous to the production cell line, e.g. Cho mif in a final product.. ... Baxalta Gmbh

Stabilized liquid and lyophilized adamts13 formulations

The present invention relates to formulations of adamts13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of adamts13 that are suitable for pharmaceutical administration. ... Baxalta Gmbh

Glycopolysialylation of non-blood coagulation proteins

A water soluble polymer, in particular polysialic acid (psa) or a modified psa (mpsa), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as psa and mpsa, are thus obtained in which the psa or mpsa is attached via a carbohydrate moiety.. ... Baxalta Gmbh

Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras

The present invention pertains to anti-mif antibodies, preferably in combination with cancer therapeutics, i.e. Chemotherapeutic agents, in the treatment of cancers containing mutant tp53 and/or mutant ras.. ... Baxalta Gmbh

Tfpi inhibitors and methods of use

The invention provides peptides that bind tissue factor pathway inhibitor (tfpi), including tfpi-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. ... Baxalta Gmbh

Method to produce an immunoglobulin preparation with improved yield

The present invention provides improved methods for the manufacturing of ivig products. These methods offer various advantages such as reduced loss of igg during purification and improved quality of final products. ... Baxalta Gmbh

Method for picking a colony of cells

The present invention relates to a method for picking a colony of cells and to producing a cell line from this colony, as well as to the cell line thus established and to use of this cell line in a method for producing a biological molecule or biological entity of interest.. . ... Baxalta Gmbh

Methods and compositions for using mhc class ii invariant chain polypeptides as a receptor for macrophage migration inhibitory factor

Methods and compositions for using the mew class ii invariant chain polypeptide, ii (also known as cd74), as a receptor for macrophage migration inhibitory factor (mif), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of mif which bind to this receptor, or which otherwise modulate the interaction of mif with cd74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered mif levels, particularly inflammatory conditions and cancer.. ... Baxalta Gmbh

Tfpi inhibitors and methods of use

The invention provides peptides that bind tissue factor pathway inhibitor (tfpi), including tfpi-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a tfpi, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.. ... Baxalta Gmbh

Removal of serine proteases by treatment with finely divided silicon dioxide

The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. ... Baxalta Gmbh

Method of producing a polypeptide or virus of interest in a continuous cell culture

Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (d) of less than about 2 d−1, and a cell density of less than about 2×107 cell/ml. ... Baxalta Gmbh

Method of producing recombinant high molecular weight vwf in cell culture

Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vwf, in particular, highly multimericwf with a high specific activity and adamts13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (nh4+) concentration. ... Baxalta Gmbh

Animal protein-free media for cultivation of cells

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. ... Baxalta Gmbh

12/28/17 / #20170369853

Formulation of sugar solutions for continuous ultracentrifugation for virus purification

The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.. ... Baxalta Gmbh

12/28/17 / #20170368193

Nucleophilic catalysts for oxime linkage

The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.. ... Baxalta Gmbh

12/21/17 / #20170362300

Oligopeptide-free cell culture media

The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/l of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/l of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/l of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/l of a polyamine.. ... Baxalta Gmbh

12/21/17 / #20170360823

Non-anticoagulant sulfated or sulfonated polysaccharides

The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (nasps), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a nasp of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. ... Baxalta Gmbh

12/07/17 / #20170349644

Factor viii with extended half-life and reduced ligand-binding properties

The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to a modified, recombinant factor viii (fviii) with extended half-life and reduced ligand-binding properties.. ... Baxalta Gmbh

11/16/17 / #20170327559

Viral inactivation using improved solvent-detergent method

The present specification discloses methods of inactivating a lipid-coat containing virus and proteins essentially free of a lipid-coat containing virus obtained from such methods.. . ... Baxalta Gmbh

10/05/17 / #20170281671

Non-anticoagulant sulfated or sulfonated synthetic polymers

The present invention provides pharmaceutical formulations including a non-anticoagulant, non-saccharide polymer that with at least one sulfate or sulfonate moiety. The pharmaceutical formulations of the invention are of use to improve blood clotting in a subject. ... Baxalta Gmbh

09/21/17 / #20170267969

Animal protein-free media for cultivation of cells

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. ... Baxalta Gmbh

09/21/17 / #20170267743

Fviii peptides for immune tolerance induction and immunodiagnostics

The present invention is related to peptides that can be used to reduce the immune response against fviii or to induce tolerance to human fviii in patients with, e.g., hemophilia a. Furthermore, the peptides can be used for immunodiagnostic purposes to detect fviii-specific cd4+ t cells to monitor patients with hemophilia a during replacement therapy and during immune tolerance induction therapy.. ... Baxalta Gmbh

09/14/17 / #20170260498

Virus filtration of cell culture media

The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. ... Baxalta Gmbh

08/24/17 / #20170240867

Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives

The invention relates to a novel polypeptide vitamin k epoxide recycling polypeptide (vkorc1) as a target for coumarin and its derivatives. The invention further provides methods for identifying coumarin derivatives, and also claims vkorc1 polypeptides and vkorc1 nucleic acids containing a sequence abnormality associated with a vkorc1 associated deficiency such as warfarin resistance, wherein the vkorc1 polypeptides and vkorc1 nucleic acids can be used for diagnosing these deficiencies. ... Baxalta Gmbh

08/24/17 / #20170240590

Nucleophilic catalysts for oxime linkage

The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.. ... Baxalta Gmbh

08/17/17 / #20170233455

Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding factor viii variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia a.. ... Baxalta Gmbh

08/10/17 / #20170227557

Method and compositions for specifically detecting physiologically acceptable polymer molecules

The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.. . ... Baxalta Gmbh

08/10/17 / #20170226487

Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression

The present invention relates to a host organism containing recombinant nucleic acids coding for the vitamin k reductase complex subunit 1 (vkorc1) and recombinant nucleic acids coding for a vitamin k dependent (vkd) protein, wherein both the recombinant vkorc1 and the recombinant vkd protein are expressed in said host organism. Further, the present invention relates to a cell culture system comprising cells which contain said recombinant nucleic acids and to methods for improving the productivity of recombinant vkd protein expression in a host organism being cultured in suitable systems.. ... Baxalta Gmbh

08/10/17 / #20170226188

Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding factor viii variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia a.. ... Baxalta Gmbh

08/10/17 / #20170224785

Subcutaneous administration of adamts13

This invention relates to methods of subcutaneous administration of adamts13 formulations to a treat a disease or condition associated with adamts13 and vwf dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of adamts13 formulations administered subcutaneously is provided herein.. ... Baxalta Gmbh

08/03/17 / #20170218051

Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs

The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin g compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-aβ, anti-rage, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived igg therapeutics. ... Baxalta Gmbh

07/13/17 / #20170196994

Models of thrombotic thrombocytopenic purpura and methods of use thereof

. . The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von willebrand factor (vwf) in various mouse strains to induce thrombotic thrombocytopenic purpura (ttp)-like symptoms for the development of a mouse model of ttp. ... Baxalta Gmbh

06/22/17 / #20170174727

Tfpi inhibitors and methods of use

. . The invention provides peptides that bind tissue factor pathway inhibitor (tfpi), including tfpi-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. ... Baxalta Gmbh

06/15/17 / #20170165419

Subcutaneous infusion device for injecting medicinal substances

A medical delivery device is provided for delivering a medicinal substance into a user's body. A foldable hub has a left wing and a right wing, where the hub is attached at one end to a tube, and at an opposite end to a needle. ... Baxalta Gmbh

06/08/17 / #20170157259

Factor viii polymer conjugates

The invention is a proteinaceous construct comprising a factor viii molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of factor viii, and methods of preparing same.. . ... Baxalta Gmbh

06/08/17 / #20170157198

Tfpi inhibitors and methods of use

The invention provides peptides that bind tissue factor pathway inhibitor (tfpi), including tfpi-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a tfpi, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify tfpi, an identify a tfpi-binding compound.. ... Baxalta Gmbh

06/01/17 / #20170153256

Methods for treating bleeding disorders using a platelet subpopulation

The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor vii (rfviia), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rfviia.. . ... Baxalta Gmbh

06/01/17 / #20170153255

Methods of measuring adamts 13 activity

The invention generally relates to methods of measuring cleaved von willebrand factor (vwf) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (adamts13) to cleave vwf in vivo. ... Baxalta Gmbh

05/11/17 / #20170128662

Packaging unit for single medical device

A packaging unit is provided for accommodating a syringe having a barrel for slidingly receiving a plunger at one end, and having an opposite needle end, and includes a housing defining a chamber for receiving the syringe. Included in the housing are a first cavity for receiving the syringe plunger, and having a first set of side walls for directly engaging a head portion of the plunger without engaging a middle portion of the plunger; a second cavity for receiving the syringe barrel, and having a set of upper walls for directly engaging an upper surface of a flange portion of the barrel; and a third cavity for receiving the needle end of the syringe, and having a second set of side walls for directly engaging a cover for enclosing the needle end. ... Baxalta Gmbh

05/04/17 / #20170119857

Method of administering porcine b-domainless fviii

The present invention provides a method of administering porcine b-domainless factor viii (obi-1) to a patient having factor viii deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant b-domainless porcine fviii, termed obi-1, has greater bioavailability compared to the natural porcine fviii partially purified from porcine plasma, termed hyate:c. ... Baxalta Gmbh

04/27/17 / #20170112906

Stabilized liquid and lyophilized adamts13 formulations

The present invention relates to formulations of adamts13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of adamts13 that are suitable for pharmaceutical administration. ... Baxalta Gmbh

03/09/17 / #20170065686

Composition exhibiting a von willebrand factor (vwf) protease activity comprising a polypeptide chain with the amino acid sequence aaggilhlellv

The invention relates to vwf cleaving entities having a molecular weight of 180 kd, 170 kd, 160 kd, 120 kd or 110 kd and an n-terminal amino acid sequence of aaggilhlellv, vwf cleaving complexes and methods for their production.. . ... Baxalta Gmbh

02/23/17 / #20170051270

Cell culture medium for adamts protein expression

The present invention provides culture mediums that are useful for the expression of adamts proteins, such as adamts13. Methods for the expression and purification of adamts proteins are also provided. ... Baxalta Gmbh

02/23/17 / #20170049885

Combination therapy of anti-mif antibodies and chemotherapeutics

The present invention pertains to anti-mif antibodies, in particular their use in combination with cancer therapeutics, i.e. Chemotherapeutics, in the treatment of cancer.. ... Baxalta Gmbh

02/16/17 / #20170044244

Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

The present invention provides, among other aspects, methods and compositions for treating a central nervous system (cns) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin g (igg) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating alzheimer's disease are provided.. ... Baxalta Gmbh

02/09/17 / #20170035835

Peptides and methods of use

The invention provides peptides, including peptides that bind and, optionally, inhibit protein s, and compositions thereof. The peptides may be used to, e.g., inhibit protein s activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify protein s, and identify a protein s binding compound.. ... Baxalta Gmbh

01/26/17 / #20170020784

Pooling device for single or multiple medical containers

A device is provided for pooling a fluid from a container unit having at least one container, and includes an inlet port having at least one inlet channel configured for receiving the fluid or ambient air, and an outlet port having at least one outlet channel configured for delivering the fluid to an attachment. Both inlet and outlet ports are disposed on the device. ... Baxalta Gmbh

01/12/17 / #20170008948

Method of producing recombinant high molecular weight vwf in cell culture

Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vwf, in particular, highly multimericwf with a high specific activity and adamts13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (nh4+) concentration. ... Baxalta Gmbh

01/05/17 / #20170002392

Medium for the protein-free and serum-free cultivation of cells

A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.. . ... Baxalta Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Baxalta Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Baxalta Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###